 |
Top 22 Vaccination and Vaccine development startups
Oct 14, 2024 | By Jason Kwon | 22 |
These startups develop new technologies to accelerate vaccine development timelines, improve vaccine efficacy and safety.
1
Country: UK | Funding: $100M
Vicebio is committed to employing the Molecular Clamp Technology to create vaccines against next-generation respiratory viruses.
Vicebio is committed to employing the Molecular Clamp Technology to create vaccines against next-generation respiratory viruses.
2
Country: France | Funding: $854.1M
Valneva is a pharmaceutical company focused on the prevention of infectious diseases with significant unmet medical need.
Valneva is a pharmaceutical company focused on the prevention of infectious diseases with significant unmet medical need.
3
Country: USA | Funding: $3.9B
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
4
Country: USA | Funding: $765M
VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
5
Country: USA | Funding: $520.6M
We’ve created a pipeline of novel vaccine and immunotherapy programs that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immune responses against a wide array of diseases.
We’ve created a pipeline of novel vaccine and immunotherapy programs that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immune responses against a wide array of diseases.
6
Country: USA | Funding: $377.5M
Affinivax is a biotechnology company developing technology to provide broad protection against diseases affecting children.
Affinivax is a biotechnology company developing technology to provide broad protection against diseases affecting children.
7
Country: UK | Funding: $240M
Barinthus Biotherapeutics is creating novel vaccines that elicit strong responses from helper and cytotoxic T-cells.
Barinthus Biotherapeutics is creating novel vaccines that elicit strong responses from helper and cytotoxic T-cells.
8
Country: Denmark | Funding: $215.5M
Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.
Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.
9
Country: Canada | Funding: $208.1M
Medicago is a biotechnology company focused on the research, development, production, and commercialization of vaccines in Canada. Acquired by Mitsubishi Tanabe Pharma
Medicago is a biotechnology company focused on the research, development, production, and commercialization of vaccines in Canada. Acquired by Mitsubishi Tanabe Pharma
10
Country: China | Funding: CN¥1.3B
Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science.
Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science.
11
Country: Austria | Funding: $150.2M
Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases.
Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases.
12
Country: USA | Funding: $132.5M
VaxInnate, a privately-held biotechnology company located in Cranbury, NJ, is pioneering breakthrough technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, a potent stimulator of the innate immune system. Using this technology, vaccines can be produced by low-cost, highly scalable recombinant DNA techniques, avoiding many of the challenges and pitfalls of egg-based or cell-culture vaccine production.
VaxInnate, a privately-held biotechnology company located in Cranbury, NJ, is pioneering breakthrough technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, a potent stimulator of the innate immune system. Using this technology, vaccines can be produced by low-cost, highly scalable recombinant DNA techniques, avoiding many of the challenges and pitfalls of egg-based or cell-culture vaccine production.
13
Country: UK | Funding: $121M
reViral is a biotechnology company that develops drugs to treat Respiratory Syncytial Virus (RSV) infection.
reViral is a biotechnology company that develops drugs to treat Respiratory Syncytial Virus (RSV) infection.
14
Country: Australia | Funding: $102.5M
Vaxxas is pioneering a next-generation vaccine delivery platform that enables robust immune system activation by targeting vaccine components to the abundant immunological cells immediately below the surface of the skin. Vaxxas' proprietary Nanopatch technology aims to provide an optimized, differentiated needle-free vaccine delivery solution that safely and cost effectively amplifies vaccine efficacy.
Vaxxas is pioneering a next-generation vaccine delivery platform that enables robust immune system activation by targeting vaccine components to the abundant immunological cells immediately below the surface of the skin. Vaxxas' proprietary Nanopatch technology aims to provide an optimized, differentiated needle-free vaccine delivery solution that safely and cost effectively amplifies vaccine efficacy.
15
Country: USA | Funding: $100M
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization dedicated to accelerating the product development timeline for diseases that disproportionately affect the world’s poorest populations, starting with malaria, tuberculosis, and diarrheal diseases—diseases that combined cause five deaths every minute.*
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization dedicated to accelerating the product development timeline for diseases that disproportionately affect the world’s poorest populations, starting with malaria, tuberculosis, and diarrheal diseases—diseases that combined cause five deaths every minute.*
16
Country: USA | Funding: $65.6M
Codagenix employs a proprietary technology platform for the construction of live attenuated viral vaccines for flu and other targets.
Codagenix employs a proprietary technology platform for the construction of live attenuated viral vaccines for flu and other targets.
17
Country: UK | Funding: $65.4M
Oxitec is a pioneer in controlling insects that spread disease and damage crops. Through world class science we have developed an innovative new solution to controlling harmful insects pests.
Oxitec is a pioneer in controlling insects that spread disease and damage crops. Through world class science we have developed an innovative new solution to controlling harmful insects pests.
18
Country: France | Funding: $59.2M
Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.
Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.
19
Country: USA | Funding: $25M
kernal biologics is mRNA vaccine and therapeutics company. It develops onco-selective mRNA immunotherapy
kernal biologics is mRNA vaccine and therapeutics company. It develops onco-selective mRNA immunotherapy
20
Country: USA | Funding: $11.4M
CaroGen Corporation is an immunotherapy company employing a virus-like vesicle (VLV) platform technology. CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
CaroGen Corporation is an immunotherapy company employing a virus-like vesicle (VLV) platform technology. CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
